The Effects of Inhaled Iloprost on Congenital Heart Disease With Eisenmenger Syndrome
This study has been completed.
Sponsor:
Gachon University Gil Medical Center
Information provided by:
Gachon University Gil Medical Center
ClinicalTrials.gov Identifier:
NCT01283958
First received: January 25, 2011
Last updated: NA
Last verified: May 2010
History: No changes posted
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Identification of the pathophysiology associated with Eisenmenger's syndrome has led to the evaluation of targeted therapies. Iloprost, a prostacyclin analogue, is one such targeted therapy used in patients with Eisenmenger's syndrome. The purpose of our study is to assess the effects of inhaled iloprost on patients with Eisenmenger's syndrome.
| Condition |
|---|
|
Eisenmenger's Syndrome |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Retrospective |
| Official Title: | Study of the Effects of Inhaled Iloprost on Congenital Heart Disease With Eisenmenger Syndrome |
Resource links provided by NLM:
MedlinePlus related topics:
Heart Diseases
Drug Information available for:
Iloprost
U.S. FDA Resources
Further study details as provided by Gachon University Gil Medical Center:
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
12 patients with Eisenmenger's syndrome diagnosed by right side cardiac catheterization
Criteria
Inclusion Criteria:
- patients with Eisenmenger's syndrome diagnosed by right side cardiac catheterization
Exclusion Criteria:
Contacts and Locations
No Contacts or Locations Provided
More Information
No publications provided
| Responsible Party: | Song I Yang, Gil Hospital, Gachon University of Medicine |
| ClinicalTrials.gov Identifier: | NCT01283958 History of Changes |
| Other Study ID Numbers: | no sponsor |
| Study First Received: | January 25, 2011 |
| Last Updated: | January 25, 2011 |
| Health Authority: | Korea: Institutional Review Board |
Keywords provided by Gachon University Gil Medical Center:
|
Iloprost, Eisenmenger's syndrome |
Additional relevant MeSH terms:
|
Eisenmenger Complex Heart Diseases Heart Defects, Congenital Cardiovascular Abnormalities Cardiovascular Diseases Congenital Abnormalities Iloprost |
Platelet Aggregation Inhibitors Hematologic Agents Therapeutic Uses Pharmacologic Actions Vasodilator Agents Cardiovascular Agents |
ClinicalTrials.gov processed this record on May 23, 2013